Management of Hepatitis C in Children - A New Paradigm
INTRODUCTION: With the advent of direct-acting antivirals (DAAs), the past decade has seen a paradigm shift in the management of hepatitis C (HCV) infection in children. In this review, we summarize the various treatment options for pediatric HCV infection, highlighting the recent changes in the management.
METHODS: A literature search was performed using the PubMed database with the relevant keywords. Filters included were human, ages 0-18 years, and the English language.
RESULTS: Initial phase of HCV treatment using conventional or pegylated interferon and ribavirin combination regimens yielded poor outcomes in children, especially in genotypes 1 and 4, with an overall sustained virologic response of 58%. Also, treatment with interferon and ribavirin combination was associated with significant side effects in up to 52% of those treated. Presently, various combinations of direct-acting antivirals (DAAs) have been approved in children above three years of age with documented evidence of high efficacy (SVR12 of 92% to 100%) and excellent safety, and the current standard of care.
CONCLUSION: With various DAA regimens now being approved for children above three years of age, the treatment of active HCV infection (HCV-RNA positive) in children has become simple. Besides the effectiveness of DAA therapy, public awareness about HCV transmission, better screening, and making the DAAs available at a subsidized price in the public sectors are necessary to eliminate HCV infection in India.
| Errataetall: |
CommentOn: J Gastroenterol Hepatol. 2022 Jun;37(6):964-972. - PMID 35263807 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:60 |
|---|---|
| Enthalten in: |
Indian pediatrics - 60(2023), 1 vom: 15. Jan., Seite 55-62 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Poddar, Ujjal [VerfasserIn] |
|---|
| Themen: |
49717AWG6K |
|---|
| Anmerkungen: |
Date Completed 17.01.2023 Date Revised 08.02.2023 published: Print CommentOn: J Gastroenterol Hepatol. 2022 Jun;37(6):964-972. - PMID 35263807 Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM351508805 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351508805 | ||
| 003 | DE-627 | ||
| 005 | 20231226051532.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1171.xml |
| 035 | |a (DE-627)NLM351508805 | ||
| 035 | |a (NLM)36639971 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Poddar, Ujjal |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Management of Hepatitis C in Children - A New Paradigm |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.01.2023 | ||
| 500 | |a Date Revised 08.02.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: J Gastroenterol Hepatol. 2022 Jun;37(6):964-972. - PMID 35263807 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: With the advent of direct-acting antivirals (DAAs), the past decade has seen a paradigm shift in the management of hepatitis C (HCV) infection in children. In this review, we summarize the various treatment options for pediatric HCV infection, highlighting the recent changes in the management | ||
| 520 | |a METHODS: A literature search was performed using the PubMed database with the relevant keywords. Filters included were human, ages 0-18 years, and the English language | ||
| 520 | |a RESULTS: Initial phase of HCV treatment using conventional or pegylated interferon and ribavirin combination regimens yielded poor outcomes in children, especially in genotypes 1 and 4, with an overall sustained virologic response of 58%. Also, treatment with interferon and ribavirin combination was associated with significant side effects in up to 52% of those treated. Presently, various combinations of direct-acting antivirals (DAAs) have been approved in children above three years of age with documented evidence of high efficacy (SVR12 of 92% to 100%) and excellent safety, and the current standard of care | ||
| 520 | |a CONCLUSION: With various DAA regimens now being approved for children above three years of age, the treatment of active HCV infection (HCV-RNA positive) in children has become simple. Besides the effectiveness of DAA therapy, public awareness about HCV transmission, better screening, and making the DAAs available at a subsidized price in the public sectors are necessary to eliminate HCV infection in India | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Ribavirin |2 NLM | |
| 650 | 7 | |a 49717AWG6K |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Interferons |2 NLM | |
| 650 | 7 | |a 9008-11-1 |2 NLM | |
| 700 | 1 | |a Umesh Reddy, D V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian pediatrics |d 1964 |g 60(2023), 1 vom: 15. Jan., Seite 55-62 |w (DE-627)NLM000375144 |x 0974-7559 |7 nnns |
| 773 | 1 | 8 | |g volume:60 |g year:2023 |g number:1 |g day:15 |g month:01 |g pages:55-62 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 60 |j 2023 |e 1 |b 15 |c 01 |h 55-62 | ||